

Curriculum Vitae**CARLO MANNINA**

Nome	Carlo
Cognome	Mannina
Data di nascita	15/07/1990
Luogo di nascita	Palermo

FORMAZIONE

April 2020 – today	Adjunct Associate Research Scientist at the Adult Cardiovascular Ultrasound Laboratories of the Division of Cardiology, Department of Medicine at the Columbia University Medical Center, New York, NY, USA
March 2020 – today	Attending physician at the Division of Internal Medicine – COVID-19 - ARNAS Civico Di Cristina Benfratelli Hospital, Palermo, Italy
Agosto 2018 – Marzo 2020	Research Fellow presso Adult Cardiovascular Ultrasound Laboratories of the Division of Cardiology, Department of Medicine at the Columbia University Medical Center, New York, NY, USA
Gen. 2019 – Marzo 2020	Research Fellow presso Cardiac Care Unit at New York Presbyterian Hospital – Columbia University Medical Center, New York, NY, USA
Nov. 2015 – oggi	Specializzazione in Medicina Interna, Università di Palermo
Aug. 2015 – Ott. 2015	Training presso Medicina d’Urgenza, ARNAS Civico Di Cristina Benfratelli Hospital, Palermo
Ott. 2008 – Lug. 2014	Laurea in Medicina e Chirurgia con votazione di 110/110 cum laude, Università di Palermo
Sett. 2013 – Giugno. 2014	Erasmus project presso Carol Davila University of Medicine and Pharmacy Bucarest, Romania
2012 – 2013	Internship presso U.O. di Neurologia, Università di Palermo
2011 – 2012	Internship presso U.O. di Endocrinologia, Università di Palermo

ESPERIENZE LAVORATIVE

Gen. 2017 – Lug. 2019	Sub-Investigator of the Clinical Trial Research Study Comparing a New Medicine “Fast-Acting Insulin Aspart” to Another Already Available Medicine “Novorapid”/”Novolog” in People with Type 2 Diabetes (onset 9) – Novo Nordisk
Nov. 2015 – Aug. 2018	Medico ambulatoriale di Diabete e rischio Cardiovascolare, Università di Palermo
Gen. 2017 – Lug. 2018	Sub-Investigator of the Clinical Trial I8B-MCITRN sponsored by Eli Lilly
Gen. 2017 – Lug. 2018	Sub-Investigator of the Clinical Trial Research Study “SUSCIPE” (Sulfonyl Ureas Correct Internal Prescription Evaluation Study) sponsored by MSD Italia

Dic. 2015 – Feb. 2018	Sub-Investigator of the Clinical Trial DUAL VIII NN 9068-4228 sponsored by Novo Nordisk
Gen. 2017 – Mag 2017	Membro di database DARWIN-T2D (DApagliflozin Real World evidence in Type 2 Diabetes)
Giug. 2017 – Dic. 2017	Sub-Investigator of the Clinical Trial Research Study “Effect of Natural Supplement Containing Chlorogenic Acid and Luteolin on Cardio-metabolic Risk Factors”
Agosto 2015 – Ott. 2015	Medico di Continuità Assistenziale, Azienda Unita' Sanitaria Locale N.6, Ustica, Palermo

COMPETENZE

Giugno 2018 – oggi	Cardiovascular Ultrasound Imaging License rilasciato da Società Italiana di Ecocardiografia e Cardiovascular Imaging (SIECVI), Milano
Ott. 2017 – Feb. 2018	Training in Ecocardiografia Transtoracica presso Policlinico Paolo Giaccone, U.O. di Medicina Interna e Cardioangiologia, Università di Palermo
Marzo 2018 – Luglio 2018	Training in Ecocardiografia Transtoracica presso ospedale Cervello U.O. di Cardiologia, Palermo
Feb. 2017 – Mag 2017	Advanced and Basic Electrocardiography License rilasciato da Società Italiana di Medicina Interna (SIMI), Roma
Mar. 2015 – Mag 2016	Advanced and Basic Cardiovascular Life Support Provider rilasciato da American Heart Association at ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione), Palermo

CONFERENZE E ALTRE ATTIVITÀ SCIENTIFICHE

2019	Reviewer per Scientific Report, Nature Publishing Group
Novembre 2019	Relatore presso American Heart Association Scientific Sessions 2019, Philadelphia, USA
Settembre 2019	COL 7 th Annual Challenges in Hypertension, Columbia University, New York, NY, USA
Giugno 2019	COL 25 th Annual Update & Intensive Review of Internal Medicine – Physician and Nurse with PA and NP, Columbia University, New York, NY, USA
Marzo 2019	COL 2nd Annual Sleep Symposium for Clinicians & Researchers, Columbia University, New York, NY, USA
Febbraio 2019	8th Annual Glomerular Disease 2019, Columbia University, New York, NY, USA
Febbraio 2019	66th Advanced Postgraduate Course, American Diabetes Association, New York, USA
Nov. 2018 – Dec. 2018	Columbia & Cornell GI XXXV Update in Gastroenterology & Hepatology
Aprile 2018	International School of Diabetes 4 th edizione, Catania

Ottobre 2016	Relatore presso 117 th Congresso Nazionale della SIMI (Società Italiana Medicina Interna) Roma
Ottobre 2017	Relatore presso 118 th Congresso Nazionale della SIMI Roma
Settembre 2017	Relatore presso 53 rd EASD (European Association of the Study of Diabetes) Annual Meeting – Lisbona – Portogallo
Marzo 2017	International School of Diabetes 3 th edizione, Camogli, Genova

PREMI E RICONOSCIMENTI INTERNAZIONALI

Mar. 2017 – Mar. 2018	Presidente regionale della Società Italiana di Diabetologia, sezione giovani YoSID (Young section of Italian Society of Diabetes)
Maggio 2018	Best young diabetes project - 27 th Congresso Nazionale della Società Italiana di Diabetologia, Rimini
Settembre 2017	Travel Grant - 53 th European Association for Study of Diabetes (EASD), Lisbona, Portugal
Aprile 2017	Grant Award - 15 th Meeting of Mediterranean Group for the Study of Diabetes, Atene, Grecia

PUBLICATIONS

- Kenji Matsumoto, Zhezhen Jin, Shunichi Homma, Mitchell S.V. Elkind, Tatjana Rundek, **Carlo Mannina**, Tetz C. Lee, Mitsuhiro Yoshita, Charles DeCarli, Clinton B. Wright, Ralph L. Sacco, Marco R. Di Tullio. 2019. Association between central blood pressure and subclinical cerebrovascular disease in the elderly: the Cardiovascular Abnormalities and Brain Lesions (CABL) study. *Hypertension*.
- Mannina C**, Jin Z, Russo C, Homma S, Elkind MS, Rundek T, Lee TC, Matsumoto K, Shames S, Sacco RL, Di Tullio M. 2019.. Effect of hypertension and diabetes on subclinical left ventricular systolic dysfunction in a predominantly elderly population-based cohort. *European Journal of Preventive Cardiology*
- Manfredi Rizzo, Dragana Nikolic, Angelo Maria Patti, **Carlo Mannina**, Giuseppe Montaldo, Brooke S. McAdams, Ali A. Rizvi, Francesco Cosentino. 2018. GLP-1 receptor agonists and reduction of cardiometabolic risk: potential underlying mechanisms. *Biochimica et Biophysica Acta - Molecular Basis of Disease*.
- Angelo Maria Patti, Khalid Al-Rasadi, Rosaria Vincenza Giglio, Dragana Nikolic, **Carlo Mannina**, Giuseppa Castellino, Roberta Chianetta, Maciej Banach, Arrigo FG Cicero, Giuseppe Lippi, Giuseppe Montaldo, Manfredi Rizzo, Peter P. Toth. 2017. State of the art paper Natural approaches in metabolic syndrome management. *Archives of Medical Science*.
- Maccora S, **Mannina C**, Bolognini N, Paladino P, Baschi R, Cosentino G, Fierro B, Vallar G, Brighina F. 2014. Menstrual cycle affects cortical excitability differently in females with migraine and in healthy controls: a new perspective by cross modal sound induced flash illusions. *The Journal of Headache and Pain*.

ABSTRACT

- 1.Nikolic D, Giglio RV , Chianetta R, Castruccio Castracani C, Sardo VA, Castellino G, Patti AM, **Mannina C**, Li Volti G, Citarrella R, Montaldo G, Rizvi AA, Rizzo M. The 53rd EASD Annual Meeting – Lisbon - from 11-15 September 2017. The GLP-1RA exenatide LAR increases circulating miR-27b in patients with type-2 diabetes: an 8-month prospective study of cardiometabolic and epigenetic response.
- 2.Castellino G, **Mannina C**, Patti AM, Galletta R, Chianetta R, Nikolic D, Giglio RV, Citarrella R, Rizvi AA, Montaldo G, Rizzo M. The 53rd EASD Annual Meeting – Lisbon - 11-15 September 2017. Exenatide LAR decreases cIMT and improves flow mediated dilation similarly in obese and non-obese type-2 diabetic patients: an 8-month prospective study.
- 3.Patti AM, **Mannina C**, Castellino G, Catalfio R, Giglio RV, Nikolic D, Chianetta R, Citarrella R, Montaldo G, Rizvi AA, Rizzo M. The 53rd EASD Annual Meeting - Lisbon - 11-15 September 2017. Improvement in flow-mediated dilatation and proinflammatory cytokines with Exenatide LAR occurred independently of baseline carotid IMT in patients with type-2 diabetes.
- 4.**Mannina C**, Castellino G, Patti AM, Bonfiglio A, Chianetta R, Giglio RV, Nikolic D, Corrado E, Citarrella R, Rizvi AA, Montaldo G, Rizzo M. The 53rd EASD Annual Meeting – Lisbon - 11-15 September 2017. Exenatide LAR improves cardio-metabolic parameters independently of the presence of endothelial dysfunction in type-2 diabetic patients: an 8 months prospective study.
- 5.Chianetta R, Giglio RV, Nikolic D, Diliberto SM, Marino Gammazza A, Castellino G, Patti AM, **Mannina C**, Citarrella R, Li Volti G, Rizvi AA, Montaldo G, Rizzo M. The 53rd EASD Annual Meeting – Lisbon - 11- 15 September 2017. Exenatide LAR improves cardio-metabolic parameters independently of baseline adiponectin in type-2 diabetic patients: an 8-month prospective study.
- 6.Chianetta R, Patti AM, Castellino G, Nikolic D, Giglio RV, **Mannina C**, Corrado E, Citarrella R, Montaldo G, Rizzo M. The 3rd CVOT Summit of the Diabetes & Cardiovascular Study Group of the EASD, Munich, Germany, 26- 27 October 2017. Exenatide LAR reduces subclinical carotid atherosclerosis and improves endothelial function in patients with type-2 diabetes: an 8-month prospective study.
- 7.Adamo A, Chianetta R, Giglio RV, Castellino G, Patti AM, Bonfiglio A, **Mannina C**, Nikolic D, Citarrella R, Montaldo G, Rizzo M. The 3rd CVOT Summit of the Diabetes & Cardiovascular Study Group of the EASD, Munich, Germany, 26- 27 October 2017. Liraglutide improves metabolic parameters and reduces intima-media thickness in obese vs non obese patients with Type 2 Diabetes: 18-month prospective study.
- 8.Castellino G, Nikolic D, Chianetta R, Giglio RV, Adamo A, Patti AM, **Mannina C**, Sardo VA, Galletta R, Bonfiglio A, Citarrella R, Montaldo G, Rizzo M. 118° Congresso Nazionale Simi, Roma 27-29 Ottobre 2017. Bergamot reduces atherogenic lipoprotein subclasses in dyslipidemic subjects with elevated baseline value of carotid intima-media thickness: a 6-month prospective study.
- 9.Chianetta R, Giglio RV, Nikolic D, Castruccio Castracani C, Diliberto SM, Castellino G, Patti AM, **Mannina C**, Citarrella R, Li Volti G, Montaldo G, Rizzo M. 118° Congresso Nazionale Simi, Roma 27-29 Ottobre 2017. Exenatide LAR improves cardio-metabolic parameters independently of baseline adiponectin in type-2 diabetic patients: an 8-month prospective study.

10. Adamo A, Giglio RV, Chianetta R, Nikolic D, Castellino G, Patti AM, **Mannina C**, Galletta R, Sardo VA, Citarrella R, Montalto G, Rizzo M. 118° Congresso Nazionale Simi, Roma 27-29 Ottobre 2017. Bergamot improves the quality of lipoprotein profile and subclinical atherosclerosis equally in both obese and not obese subjects with moderate hypercholesterolemia: a 6-month prospective study.
11. **Mannina C**, Castellino G, Patti A, Giglio RV, Chianetta R, Nikolic D, Bonfiglio A, Sardo VA, Galletta R, Catalfio R, Citarrella R, Montalto G, Rizzo M. 118° Congresso Nazionale Simi, Roma 27-29 Ottobre 2017. Liraglutide improves carotid intima-media thickness in pre-elderly and elderly patients with type-2 diabetes: an 18-month prospective, real life study.
12. Giglio RV, Patti AM, Castellino G, **Mannina C**, Nikolic D, Chianetta R, Galletta R, Sardo VA, Bonfiglio A, Catalfio R, Citarrella R, Montalto G, Rizzo M. 118° Congresso Nazionale Simi, Roma 27-29 Ottobre 2017. Liraglutide improves metabolic parameters and reduces intima-media thickness in obese patients with type 2 diabetes: 18-month prospective study.
13. Chianetta R, Giglio RV, Nikolic D, Patti AM, Castellino G, **Mannina C**, Diliberto SM, Fiorentino V, Ruggirello D, Carruba G, Citarrella R, Montalto G, Rizzo M. VII Congresso Nazionale SINUT, Bologna, 19-20 maggio 2017. Pasta with Opuntia reduces atherogenic lipoproteins: one month prospective pilot study.
14. Nikolic D, Li Volti G, Corrado E, Giglio RV, Chianetta R, Castellino G, **Mannina C**, Patti AM, Provenzano F, Provenzano V, Montalto G, Rizvi AA, Rizzo M. 77th Scientific Sessions June 9 - 13, 2017, San Diego, California Exenatide LAR Improves Endothelial Function: an 8-Month Prospective Study.
15. Giglio RV, Li Volti G, Corrado E , Nikolic D, Chianetta R, Castellino G, **Mannina C**, Patti AM, Marino Gammazza A, Provenzano F, Provenzano V, Montalto G, Rizvi AA, Rizzo M. 77th Scientific Sessions June 9 - 13, 2017, San Diego, California. Exenatide LAR Improves Carotid Intima-Media Thickness and Increases Adiponectin Plasma Levels in Patients with Type-2 Diabetes: an 8-Month Prospective Study.
16. Castellino G, Li Volti G, Corrado E , Nikolic D , Giglio RV , Chianetta R, **Mannina C**, Diliberto SM, Patti AM, Provenzano F , Provenzano V, Montalto G , Rizvi AA , Rizzo M. 77th Scientific Sessions June 9 - 13, 2017, San Diego, California. Exenatide LAR Shows Greater Cardio-Metabolic Control in Type-2 Diabetic Patients with Liver Steatosis Rather than Those without It: an 8-Month Prospective Study.
17. Patti AM, Li Volti G, Castruccio Castracani C, Nikolic D , Chianetta R, Giglio RV , Castellino G, **Mannina C**, Diliberto SM, Provenzano F, Provenzano V, Montalto G, Rizvi AA, Rizzo M. 77th Scientific Sessions June 9 - 13, 2017, San Diego, California. Liraglutide Increases Specific MicroRNAs and Decreases Atherogenic Lipoproteins in Diabetic Patients: A 4-Month Pilot Study.
18. Chianetta R, Li Volti G, Nikolic D, Patti AM, Castellino G, **Mannina C**, Giglio RV, Bonfiglio A, Fiorentino V, Ruggirello D, Provenzano F, Provenzano V, Montalto G, Rizzo M. 15th meeting of the Mediterranean Group for the Study of Diabetes, Athens, from 27 to 29, April 2017. The reduction in small dense lowdensity lipoproteins by liraglutide is independently associated with reduced carotid atherosclerosis in patients with type-2 diabetes.
19. Castellino G, Magán-Fernández A, Li Volti G, Nikolic D, Patti AM, **Mannina C**, Chianetta R, Giglio RV, Catalfio S, Diliberto SM, Provenzano F, Provenzano V, Montalto G, Rizzo M. Athens, from 27 to 29, April 2017. 15th meeting of the Mediterranean Group for the Study of Diabetes,. The beneficial

effects of liraglutide on cardio-metabolic parameters are not affected by menopausal status: an 18-month prospective study.

20. Giglio RV, Corrado E, Li Volti G, Nikolic D, Patti AM, Castellino G, **Mannina C**, Chianetta R, Sardo VA, Vanella L, Provenzano F, Provenzano V, Montaldo G, Rizzo M. Athens - from 27 to 29, April 2017. 15th meeting of the Mediterranean Group for the Study of Diabetes,. Exenatide LAR reduces subclinical carotid atherosclerosis and improves endothelial function in patients with type-2 diabetes: an 8-month prospective study.